Mycobacterium Smegmatis Patents (Class 435/866)
-
Patent number: 7740867Abstract: Disclosed are methods for the determination of virulence determinants in bacteria and in particular bacteria of the genus Mycobacterium. Also disclosed are compositions and methods for stimulating an immune response in an animal using bacteria and virulence determinants identified by the methods of the present invention.Type: GrantFiled: November 27, 2007Date of Patent: June 22, 2010Assignee: Board of Regents of the University of NebraskaInventors: Raul G. Barletta, N. Beth Harris
-
Patent number: 7094403Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: January 17, 2003Date of Patent: August 22, 2006Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 6833135Abstract: The present invention discloses a DNA fragment that can direct the insertion of heterologous DNA into a specific site (tRNAAla gene) of Mycobacterium spp. genome. This DNA fragment includes the attachment site region (attP) and the integrase gene of the mycobacteriophage Ms6. Heterologous DNA linked to this DNA fragment can be carried into the mycobacterial genome through a site-specific integration mechanism. A new DNA integration process is disclosed that consists in providing the integrase gene on a suicide vector, that transiently produces the integrase required for the insertion of the gene or genes linked to the Ms6 attP region contained in a separated plasmid vector. This process allows the construction of highly stable recombinant mycobacteria which may be used as vaccines and/or therapeutic vehicles.Type: GrantFiled: June 3, 1999Date of Patent: December 21, 2004Assignee: Laboratorio Medinfar Produtos Farmaceuticos, LDA.Inventors: Jose A. Frazao Moniz Pereira, Alcino Freitas Vieira, Elsa M. Ribeiro Dos Santos-Anes, Miguel A. Da Costa Garcia, Paulo J. Da Silva Alves
-
Patent number: 6821769Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.Type: GrantFiled: July 31, 2001Date of Patent: November 23, 2004Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
-
Patent number: 6752994Abstract: A mutated mycobacterium selected from the class consisting of mutated M. bovis-BCG, mutated M. tuberculosis, and mutated M. leprae. The mutation of M. bovis-BCG, M. tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.Type: GrantFiled: July 3, 2001Date of Patent: June 22, 2004Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
-
Patent number: 6566121Abstract: A mutated mycobacterium selected from the class consisting of mutated M.bovis-BCG, mutated M.tuberculosis, and mutated M. leprae. The mutation of M.bovis-BCG, M.tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.Type: GrantFiled: May 5, 1997Date of Patent: May 20, 2003Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
-
Patent number: 6517845Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: November 12, 1999Date of Patent: February 11, 2003Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 6403100Abstract: This invention provides for novel attenuated strains of Mycobacterium tuberculosis and M. bovis. Attenuation is achieved by eliminating or by downregulating the expression of the &agr;-crystallin heat shock protein gene (“acr gene”). The invention provides for vaccines and methods of vaccinating mammals for protection against Mycobacterium sp. that cause tuberculosis.Type: GrantFiled: June 27, 2000Date of Patent: June 11, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Clifton E. Barry, III, Ying Yuan, Deborah D. Crane
-
Patent number: 6268201Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.Type: GrantFiled: October 23, 1998Date of Patent: July 31, 2001Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
-
Patent number: 6229001Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.Type: GrantFiled: December 15, 1997Date of Patent: May 8, 2001Assignee: Southern Research InstituteInventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
-
Patent number: 6004771Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.Type: GrantFiled: August 11, 1997Date of Patent: December 21, 1999Assignee: Integrated Research Technology, LLCInventor: Charles G. Thornton
-
Patent number: 5994346Abstract: Exochelins can be used to prevent damage to organs for transplant from the formation or presence of the .circle-solid.OH radical. In particular, the invention is directed to the administration of exochelins to the organ prior to or coincidental with removal from a donor, storage, implantation in a recipient or in conjunction with reestablishment of flow of body fluids to the organ.Type: GrantFiled: October 30, 1997Date of Patent: November 30, 1999Assignee: Regents of the University of CaliforniaInventors: Marcus A. Horwitz, Lawrence D. Horwitz
-
Patent number: 5985596Abstract: The present invention relates to a method for enhancing the time of response of an assay for a first bacterium, wherein: a) the first bacterium is exposed to infection by phage particles to which the first bacterium is permissive; b) the infected bacterium is treated to inactivate exogenous phage particles; c) the treated bacterium is cultivated in the presence of a second bacterium which is permissive to infection by the phage or its replicand and which has a doubling rate greater than the effective doubling rate of the first bacterium; and d) assessing the extent of plaque formation and/or of second bacterium growth in the cultivated second bacterium cells.Type: GrantFiled: July 27, 1998Date of Patent: November 16, 1999Assignee: Biotec Laboratories LimitedInventor: Stuart Mark Wilson
-
Patent number: 5837677Abstract: The invention is directed toward the use of desferri-Exochelins to destroy cancer cells or retard or eliminate the growth of those cancer cells.Type: GrantFiled: June 25, 1997Date of Patent: November 17, 1998Assignee: Keystone Biomedical, Inc.Inventors: Lawrence D. Horwitz, Kathryn B. Horwitz
-
Patent number: 5837480Abstract: This invention relates to InhA enzyme crystals and to methods of growing said crystals. This invention is further directed to the utilization of said crystals to determine the three dimensional structure of InhA enzyme utilizing heavy atom derivatives of said crystals, and to the identification and development of compounds which inhibit the biochemical activity of InhA enzyme in bacteria and plants.Type: GrantFiled: August 21, 1996Date of Patent: November 17, 1998Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva UniversityInventors: James Sacchettini, John Blanchard, William R. Jacobs, Jr.
-
Patent number: 5830475Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.Type: GrantFiled: June 5, 1995Date of Patent: November 3, 1998Assignee: Whitehead Institute for Biomedical ResearchInventors: Anna Aldovini, Richard A. Young
-
Patent number: 5721209Abstract: Exochelins can be used to prevent damage to living tissue from the formation or presence of the (.cndot.OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins as well as other applications of these materials in the treatment and diagnosis of disease in mammals.Type: GrantFiled: February 3, 1995Date of Patent: February 24, 1998Assignee: The Regents of the University of CaliforniaInventors: Lawrence D. Horwitz, Marcus A. Horwitz, Bradford W. Gibson, Joseph Reeve
-
Patent number: 5658749Abstract: A method for the preparation of Mycobacteria from any liquid, semi-solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.Type: GrantFiled: February 23, 1995Date of Patent: August 19, 1997Assignee: Corning Clinical Laboratories, Inc.Inventor: Charles G. Thornton
-
Patent number: 5523214Abstract: A method of visually demonstrating the growth of such microorganisms as fungi, yeasts, and bacteria, especially mycobacteria, identifying them, and testing them for sensitivity to antibiotics by the color change of a specific redox indicator system. A mixture of the redox indicators Methylene Blue and resazurin is added to the culture medium. Iron(III) salts mixed with K.sub.3 Fe(CN).sub.6, Iron(II) salts mixed with K.sub.4 Fe(CN).sub.6, or sodium tungstate (Na.sub.2 WO.sub.4) is added to the culture medium.Type: GrantFiled: May 9, 1994Date of Patent: June 4, 1996Assignee: Biotest AktiengesellschaftInventor: Jurgen Horn
-
Patent number: 4777130Abstract: A 60-like antigens isolated in a one-step reaction from the bacterial cytoplasma of Mycobacteria are useful for the production of diagnostic tests.Type: GrantFiled: December 5, 1984Date of Patent: October 11, 1988Assignee: Andra BiologicalsInventor: Roland F. Maes